Rheoxtech Post Pitch Call

Rheoxtech Presented at WAA's 11-Jul Life Sciences Pitch Event.

A post pitch call is on Friday, 26-Jul-2024 at 7am PT // 10pm ET.

Please submit due diligence questions for Headache Sciences: Rheoxtech_DD_Pitch Follow-up Questions_11-Jul-2024

Joining information will be sent upon registration.

  Rheoxtech is a medical device company developing solutions for reperfusion injury following acute myocardial infarctions

SOURCED BY WAA PARTNER SYNDICATE

PROBLEM: Annually, the U.S. sees approximately 800,000 acute MI cases. Despite current treatments, about 10% of patients die initially, and another 10% develop Cardiogenic Shock, which has up to a 40% mortality rate. New interventions are essential to improve survival rates.

SOLUTION: RHEOX™ Reperfusion System A first in class cardiac reperfusion system (Pump Base Unit, Disposable Cartridge, and Perfusion Catheter) that is intended for use in acute myocardial infarction patients, predicted to save lives, improve patient quality of life, and result in considerable cost savings.

DEAL LEAD: Ramesh Gupta // Ramesh Gupta on Slack

• Rheoxtech Pitch Recording_11-Jul-2024
• Rheoxtech Pitch Deck
• Rheoxtech Deal Terms
• Rheoxtech SAFE
• Rheoxtech allocation for WAA: no max
• Rheoxtech on Dealum (view company profile, and in "DOCUMENTS" tab, pitch deck, deal terms, pitch recording, submit due diligence questions, etc.)
• 1-rheoxtech on Slack